NCT02328105View on ClinicalTrials.gov

LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

11

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

June 15, 2017

Study Completion Date

December 6, 2019

Conditions

Lung Cancer

Interventions

DRUG

Carboplatin

Dosing: AUC = 6; on Day 1

DRUG

Abraxane

100 mg/m\^2; Days 1, 8, 15

Trial Locations (1)

28203

Levine Cancer Institute, Charlotte

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Celgene

INDUSTRY

lead

Wake Forest University Health Sciences

OTHER